Sensus Healthcare
Market Cap
US$43.2m
Last Updated
2020/09/28 05:37 UTC
Data Sources
Company Financials +
Executive Summary
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and fair value.
Similar Companies
Share Price & News
How has Sensus Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SRTS has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
7.4%
SRTS
-1.7%
US Medical Equipment
-0.8%
US Market
1 Year Return
-56.3%
SRTS
16.5%
US Medical Equipment
13.8%
US Market
Return vs Industry: SRTS underperformed the US Medical Equipment industry which returned 16.5% over the past year.
Return vs Market: SRTS underperformed the US Market which returned 13.8% over the past year.
Shareholder returns
| SRTS | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.4% | -1.7% | -0.8% |
| 30 Day | -1.1% | -3.5% | -5.7% |
| 90 Day | -14.4% | 12.2% | 8.6% |
| 1 Year | -56.3%-56.3% | 17.5%16.5% | 16.4%13.8% |
| 3 Year | -47.6%-47.6% | 70.0%65.6% | 36.9%27.8% |
| 5 Year | n/a | 139.5%121.3% | 85.0%64.2% |
Price Volatility Vs. Market
How volatile is Sensus Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Sensus Healthcare, Inc.'s (NASDAQ:SRTS) Intrinsic Value Is Potentially 73% Above Its Share Price4 months ago | Simply Wall St
Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates5 months ago | Simply Wall St
Should You Be Pleased About The CEO Pay At Sensus Healthcare, Inc.'s (NASDAQ:SRTS)Valuation
Is Sensus Healthcare undervalued compared to its fair value and its price relative to the market?
43.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SRTS ($2.62) is trading below our estimate of fair value ($4.66)
Significantly Below Fair Value: SRTS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SRTS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: SRTS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRTS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SRTS is good value based on its PB Ratio (2x) compared to the US Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is Sensus Healthcare forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
107.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRTS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SRTS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SRTS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SRTS's revenue (61% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: SRTS's revenue (61% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SRTS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Sensus Healthcare performed over the past 5 years?
-28.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRTS is currently unprofitable.
Growing Profit Margin: SRTS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SRTS is unprofitable, and losses have increased over the past 5 years at a rate of 28.5% per year.
Accelerating Growth: Unable to compare SRTS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRTS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: SRTS has a negative Return on Equity (-26.52%), as it is currently unprofitable.
Next Steps
Financial Health
How is Sensus Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: SRTS's short term assets ($27.1M) exceed its short term liabilities ($4.8M).
Long Term Liabilities: SRTS's short term assets ($27.1M) exceed its long term liabilities ($2.8M).
Debt to Equity History and Analysis
Debt Level: SRTS's debt to equity ratio (4.6%) is considered satisfactory.
Reducing Debt: SRTS's debt to equity ratio has reduced from 14.2% to 4.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SRTS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SRTS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 8.5% per year.
Next Steps
Dividend
What is Sensus Healthcare current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRTS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRTS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRTS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRTS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRTS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Joe Sardano (67 yo)
10.25yrs
Tenure
US$466,800
Compensation
Mr. Joseph C. Sardano, also known as Joe, is Co-Founded Sensus Healthcare, Inc. in 2010 and has been its Chairman of the Board, Chief Executive Officer and President since June 2010. Mr. Sardano serves as ...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD466.80K) is about average for companies of similar size in the US market ($USD604.44K).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.25yrs | US$466.80k | 9.32% $ 4.0m | |
| Co-Founder & Executive VP | 10.67yrs | US$521.26k | 5.64% $ 2.4m | |
| Chief Financial Officer | 0.67yr | no data | 0.034% $ 14.7k | |
| Chief Operating Officer | 0.67yr | no data | 0.030% $ 13.2k | |
| Chief Technology Officer | 0.67yr | no data | 0.063% $ 27.0k | |
| VP, General Counsel & Corporate Secretary | 3.67yrs | no data | 0.082% $ 35.3k | |
| Medical Director & Member of Medical Advisory Board | 7.08yrs | no data | no data | |
| Clinical Director & Member of Medical Advisory Board | no data | no data | no data |
2.2yrs
Average Tenure
59yo
Average Age
Experienced Management: SRTS's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.25yrs | US$466.80k | 9.32% $ 4.0m | |
| Medical Director & Member of Medical Advisory Board | 7.08yrs | no data | no data | |
| Clinical Director & Member of Medical Advisory Board | no data | no data | no data | |
| Non-Employee Director | 4.17yrs | US$60.00k | 0.36% $ 157.7k | |
| Chairman of Medical Advisory Board | 9.58yrs | no data | no data | |
| Independent Director | 8.58yrs | US$60.00k | 0.36% $ 157.0k | |
| Member of Medical Advisory Board | 3.67yrs | no data | no data | |
| Independent Director | 8.58yrs | US$60.00k | 0.99% $ 428.6k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.92yrs | US$60.00k | 0.12% $ 52.4k | |
| Member of Medical Advisory Board | no data | no data | no data |
7.8yrs
Average Tenure
69yo
Average Age
Experienced Board: SRTS's board of directors are considered experienced (7.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sensus Healthcare, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sensus Healthcare, Inc.
- Ticker: SRTS
- Exchange: NasdaqCM
- Founded: 2010
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$43.236m
- Shares outstanding: 16.50m
- Website: https://www.sensushealthcare.com
Number of Employees
Location
- Sensus Healthcare, Inc.
- 851 Broken Sound Parkway NW
- Suite 215
- Boca Raton
- Florida
- 33487
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SRTS | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jul 2016 |
| 5TX | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2016 |
Biography
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/28 05:37 |
| End of Day Share Price | 2020/09/25 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.